Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.705    0.455 (10.71%)
Bid:
4.70
Ask:
4.74
Spread: 0.04 (0.851%)
Market Cap: £225.82m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Directorate Change

8 Jun 2011 07:00

RNS Number : 0183I
Seeing Machines Limited
08 June 2011
 



8 June 2011

SEEING MACHINES (the "Company")

 

CEO TO DEPART AT END OF CONTRACT

Seeing Machines Limited (AIM:SEE), a leading developer of advanced vision based industrial systems, announces today that CEO and Director Dr Nick Cerneaz will leave the Company in July 2011.

Dr Cerneaz has been with the Company since 2005 and took over as CEO in September 2005 and led the Company at the time of its listing on AIM in December 2005. For the six years that he has been with the company he has commuted to the Canberra head office from his home in Sydney where he lives with his wife and young family. Dr Cerneaz and the Board of Seeing Machines have agreed his tenure as CEO will conclude at the end of this contract. Dr Cerneaz has also agreed to assist the Company in a consulting capacity throughout a handover period as required.

The Board is currently conducting a search for a replacement to lead the Company, as it seeks to move through the next phase of growth and commercialisation. Seeing Machines manufactures a range of world leading products from fatigue management tools through to 3D visualisation and medical technologies, and the Board remains committed to driving a strategy of growth through commercialisation of these technologies and products.

Dr Cerneaz commented: "I have very much enjoyed the efforts and contribution I have made at Seeing Machines and greatly valued the opportunity to work with such a dedicated, professional and energetic team. We have successfully moved the Company through an extensive period of development and laid the foundations for tremendous commercial success ahead, particularly with significant contracts established in our DSS and faceAPI businesses and strong pipelines ahead. I wish to take this opportunity to thank all my colleagues and the stakeholders in the business that have encouraged and supported our efforts and wish the company well in its forward endeavours."

Chairman Bill Mobbs commenting on Dr Cerneaz's departure said: "The Board is extremely grateful to Nick for his leadership of the Company throughout his tenure which was characterised by strong commitment, professionalism, drive and enthusiasm in taking the Company forward. We wish Nick well in his future endeavours and join with everyone at Seeing Machines in thanking Nick wholeheartedly for his efforts on behalf of the Company. "

Enquiries:

Seeing Machines Limited

Bill Mobbs, Chairman

+61 (0) 2 6103 4700

Daniel Stewart & Company plc

Oliver Rigby

+44 (0) 20 7776 6550

Walbrook PR Ltd

 

Paul McManus

 

Paul Cornelius

+44 (0) 20 7933 8780+44 (0) 7980 541 893, paul.mcmanus@walbrookpr.com

+44 (0) 7866 384 707, paul.cornelius@walbrookir.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMGGVDNRGMZM
Date   Source Headline
22nd Mar 20239:16 amRNSPDMR Shareholding
17th Mar 20239:03 amRNSDirector/PDMR Shareholding
16th Mar 202311:12 amRNSDirector/PDMR Shareholding
15th Mar 20237:00 amRNSPDMR Shareholding
14th Mar 20237:00 amRNSPDMR Shareholding
13th Mar 20239:24 amRNSNo exposure to Silicon Valley Bank
9th Mar 20236:09 pmRNSDirector/PDMR Shareholding
8th Mar 20233:33 pmRNSDirector/PDMR Shareholding
8th Mar 20233:30 pmRNSDirector/PDMR Shareholding
6th Mar 20237:00 amRNSHalf year results and financial report
22nd Feb 20237:00 amRNSHalf year trading update and quarterly KPIs
15th Feb 20237:00 amRNSNotice of Results & Investor Presentation
8th Feb 20239:46 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSSeeing Machines and Mobileye to target Aftermarket
26th Jan 20239:36 amRNSDirector/PDMR Shareholding
25th Jan 202310:24 amRNSDirector/PDMR Shareholding
16th Jan 202310:28 amRNSDirector/PDMR Shareholding
13th Jan 20238:50 amRNSDirector/PDMR Shareholding
12th Jan 202310:05 amRNSDirector/PDMR Shareholding
11th Jan 202311:19 amRNSDirector/PDMR Shareholding
5th Jan 20237:00 amRNSLaunch of Silicon Platform with OMNIVISION
4th Jan 20237:00 amRNSThree Collaborations to be showcased at CES 2023
3rd Jan 20237:00 amRNSSeeing Machines to exhibit DMS & OMS at CES 2023
22nd Dec 20227:02 amRNSSeeing Machines awarded additional OEM program
7th Dec 20229:01 amRNSPDMR Shareholding
6th Dec 20228:58 amRNSPDMR Shareholding
5th Dec 20227:00 amRNSPDMR Shareholding
2nd Dec 20227:00 amRNSPDMR Shareholding
29th Nov 20223:31 pmEQSSeeing Machines CEO talks new performance indicators and focus on annual growth
29th Nov 202210:43 amRNSPDMR Shareholding
28th Nov 20228:53 amRNSResult of AGM
24th Nov 202212:43 pmRNSPDMR Shareholding
23rd Nov 20227:00 amRNSKey Performance Indicators Q1 FY 2023
21st Nov 202211:46 amRNSPDMR Shareholding
18th Nov 20227:00 amRNSPDMR Shareholding
16th Nov 20227:00 amRNSPDMR Shareholding
14th Nov 20227:00 amRNSPDMR Shareholding
11th Nov 20227:00 amRNSAppointment of Chief Financial Officer
1st Nov 202211:17 amRNSDirector/PDMR Shareholding
27th Oct 20228:18 amRNSNotice of AGM
27th Oct 20227:00 amRNSYear End Results – FY2022
6th Oct 20227:00 amRNSExclusive agreement with Magna & US$65m investment
15th Sep 20228:50 amRNSTown Hall (Revised Date)
9th Sep 20227:30 amRNSPostponement of London presentation
16th Aug 20227:00 amRNSSeeing Machines London presentation
15th Aug 20227:00 amRNSFY2022 trading update
2nd Aug 202212:30 pmRNSInvestor newsletter update
16th Jun 20227:00 amRNSSeeing Machines awarded additional OEM program
6th Jun 20227:22 amRNSNew Tier One contract takes OEM customers to 10
10th May 20227:00 amRNSSeeing Machines appointment with Japanese OEM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.